1. Life Sciences in British Columbia:
Creating an Enabling Environment for Success

2. About LifeSciences British Columbia
Supports and represents the biotechnology, medical device and greater life sciences community of British Columbia through
Leadership
Advocacy
Promotion of our world-class science and biotechnology industry
Facilitation of partnering and investment
Approximately 300 members, including companies and research institutions involved in:
Biopharmaceuticals
Medical Devices
BioProducts & BioEnergy
Agricultural and Forest Biotech
Industrial Biotech
Marine Biotech
LifeSciences BC is a not-for-profit, non-government, industry-funded association

3. Our Vision British Columbia realizes its full potential to be a world leader in life sciences; generating a robust and sustainable bio-economy in British Columbia and Canada built on strong partnerships between industry, academia and government.
Our Mission
To represent and support British Columbia’s life sciences industry and research community through advocacy, facilitation of economic development, and the marketing and promotion of our industry globally, thus fostering an enabling environment for success.

4. LSBC Supports Each of these Sectors Through Four Strategic Thrusts:
Marketing and Promoting BC’s Life Sciences Industry and Scientific Excellence Within and Outside Canada
Facilitating Economic Development in BC through the Active Facilitation of Investment and Partnering
Development and Support of our Human Capital
Advocacy – Undertaking Relevant Public Policy Initiatives and Working with the Policy Makers to Strengthen the Life Sciences Sector and Create an Enabling Environment for Success

6. British Columbia is the 7th Largest Biopharma Cluster in North America

7. World-Class Research is the Basis of our Industry

8. Genome BC
Research organization that invests in and manages large-scale genomics and proteomics research projects and science and technology platforms across life sciences sectors of economic significance to BC
Investing $400M in life science research ( ) in BC via regional, national and international investment
Fostered a New Genomics Economy in BC in under five years
Over 800 leading experts and research staff on 22 Genome BC projects and 5 platforms
Recent recipient of $50 million from the Provincial Government for climate change research

9. Michael Smith Foundation for Health Research
Created in 2001 by the Province of BC to build BC’s capacity for excellent health research
Investing $225 million in health research
Operates as non profit society
Goal – to increase BC’s ability to attract health researchers and increase BC’s share of federal health research funding

10. UBC “Patent Powerhouse”
Ranked 9th in N.A. by The Scientist for generating high-quality, patentable scientific research – number one in Canada.
Ranked 8th in N.A., by the Milken Institute and number one in Canada for its tech transfer and commercialization activities.
UBC led Canada in Gross Income from technology licenses in 2005 with $15,986,000 (91 licenses and options).
Published in June 20, 2005 issue of
The Scientist, pg 40
Survey conducted by 1790 Analytics.

11. SFU Research
SFU received close to $70 million in research revenue in 2007/2008, the majority won in open competition outside British Columbia
Approximately 550 Technology Disclosures have been made at SFU between , with approximately 400 patent applications filed
65+ license agreements to date; approx. 75 spin-off companies formed
SFU ranks second in Canada in the number of start-up companies formed per $1 million invested in research and fourth in the number of US patents issued per $1 million

12. UVic Research
In 16 years, UVic’s Innovation and Development Corporation (IDC) has:
filed over 294 national and international patent applications
helped incorporate 55+ spin-off companies based on UVic research or UVic student entrepreneurial initiatives
Student ideas make up 35 per cent of IDC's annual invention disclosures. Eight of the IDCspin-off companies have been founded by UVic students.
UVic researchers were awarded more than $106 million in outside research grants and contracts in 2007/08. This more than doubles the research support of the previous five-year period
Leads all Canadian comprehensive universities in size and number of medical and science grants per faculty member
Purchased the Vancouver Island Technology Park for $20.2 million. The park generates $280 million in direct, indirect and induced revenue, and creates more than 2,000 local jobs.

13. Selected BC Centres of Excellence in Health Research
BC Cancer Agency
Brain Research Centre, UBC
Prostate Centre, VGH
Blood Research Centre, UBC
HIV/AIDS Centre of Excellence, St. Paul’s
Centre for Molecular Medicine & Therapeutics
Providence Heart & Lung Institute, St. Paul’s
iCord Spinal Chord Research Centre
Centre for Drug Research and Development
TRIUMF: Canada's National Laboratory for Particle and Nuclear Physics & Medicine

14. BC Cancer Agency Diverse population of approx. 4 million people
19,000 new patients per year
Provincial-wide screening programs
13 tumour groups
Best outcomes in Canada
has mandate for cancer control and cancer research in the province
A single population-based cancer control program
A centralized database of all cancer outcomes (CAIS)
A living laboratory for cancer control research

15. BC Cancer Agency’s Research Centre
9 research departments, conducting research into
more than 100 types of cancer
Advanced Therapeutics
Cancer Control Research
Cancer Endocrinology
Cancer Genetics and Developmental Biology
Cancer Imaging
BC Cancer Agency’s Michael Smith Genome Sciences Centre
Medical Biophysics
Terry Fox Laboratory
The Agency’s Trev & Joyce Deeley Research Centre

16. The Centre for Drug Research and Development (CDRD)
A new breakthrough initiative to commercialize technologies from eight British Columbia Research institutions
Recipient of approx. $75 million dollars in recent federal and provincial investment
A unique hybrid model that combines public research infrastructure with a corporate commercialization entity
Puts British Columbia at the forefront of turning public investment in research into commercial products.

17. The Result to Date: Significant Commercial Success
BC is home to three of the world’s first profitable biotech companies: QLT Inc., Angiotech Pharmaceuticals and Aspreva Pharmaceuticals
BC has also been home to world-class companies such as ID BioMedical and AnorMED which were acquired by GSK and Genzyme respectively
Four of the top ten biotech companies in Canada are headquartered in British Columbia
QLT’s Visudyne is one of the most successful ophthalmology products ever, with 2005 worldwide sales toping $480M US.
Angiotech’s lead product is the paclitaxel-eluting coronary stent, TAXUS® which has now been implanted in millions of patients worldwide, and is the most successfully launched product in medical history sales of TAXUS totaled $2.69B US

18. Top Global Partners Have Been Critical to This Success
BC Company
Partner
Product
Angiotech
Boston Scientific
Taxus Stent
QLT
Novartis
Visudyne
Xenon
Takeda
Pain Product
Cardiome
Astellas
Vernakalant
Aspreva
Roche
Cellcept
Obesity & metabolic disorders
Neuromed
MERCK

19. A High Return on Investment has Resulted
British Columbia has one of the best returns on investment per research dollar in North America
Our companies have created tremendous value for partners and investors
Acquisitions have brought international investment to BC

20. For further information on British Columbia’s growing life sciences industries, please contact:
LifeSciences British Columbia
# West Georgia Street
Vancouver, BC
Canada V6E 4A2
Tel: (604)
Web: